IDCR, a forum for correctional problem solving,
targets correctional administrators and HIV/AIDS and hepatitis care
providers including physicians, nurses, outreach workers, and case
managers. Continuing Medical Education credits are provided by Nova Southeastern University Health Professions Division (NSU) to physicians who accurately respond to the questions on the last page of the newsletter.
The
editorial board and contributors to IDCR include national and regional
correctional professionals, selected on the basis of their experience
with HIV and hepatitis care in the correctional setting and their
familiarity with current HIV and hepatitis treatment. We encourage
submissions, feedback, and correspondence from our readership.
ABOUT THIS CONTINUING EDUCATION ACTIVITY
NSU designates this educational activity
for a maximum of 1 AMA PRA Category 1 Credit(s)T. Physicians should
only claim credit commensurate with the extent of their participation
in the activity. Statements of credit will be mailed within 6 to 8
weeks following the program.
To obtain credit read the Main Article and 101 sections of the monograph. When completed with both items download the PDF version ( click here to download free adobe reader) | (System requirements) of the monograph located on the sidebar and complete the post test, credit application and evaluation form at the end of the monograph. You must receive a test score of at least 75% and respond to all evaluation questions to receive a certificate. To receive your certificate mail or fax the post test, credit application and evaluation to:
IDCR
146 Clifford Street
Providence, RI 02903
or fax it to (401)272-7562
The material presented in this activity does not reflect the views of NSU. These materials may discuss uses and dosages for therapeutic products that have not been approved by the United States Food and Drug Administration. NSU and IDCR do not recommend the use of any product outside of the labeled indications. A qualified health care professional should be consulted before using any therapeutic product discussed. All readers and continuing education participants should verify all information and data before treating patients or employing any therapies described in this continuing education activity.
Release Date: 6-1-08
End Date: 6-30-09
|
COMMERCIAL SUPPORTERS
OBJECTIVES
- The learner will be able to describe the epidemiology, transmission, symptoms, and signs of noroviruses.
- The learner will be able to explain the most effective norovirusinfection control and containment methods.
- The learner will be able to discuss useful ways to educate inmates, health care professionals, and administrative staff on the prevention and containment of noroviruses.
|
PURPOSE STATEMENT AND TARGET AUDIENCE
The purpose of this monograph is to increase the knowledge of physicians in correctional systems regarding strategies for the prevention, containment, and treatment of noroviruses.
|
DISCLOSURES
Faculty Disclosure
NSU have no financial relationships to disclose.
In accordance with the Accreditation Council for NSU, the faculty for this
activity have been asked to complete Conflict of Interest Disclosure
forms. |
|
Executive Editor
Anne S. De Groot, MD
Adjunct Associate Professor
Warren Alpert School of Medicine of Brown University
Nothing to Disclose
Editor in Chief
Joseph Bick, MD
Chief Deputy, Clinical Services California Medical Facility
California Department of Corrections
Nothing to Disclose
Deputy Editor
David Alain Wohl, MD
Associate Professor of Medicine
Division of Infectious Diseases
AIDS Clinical Research Unit
The University of North Carolina- Chapel Hill
Disclosures: Speaker: Abbott Laboraties, Gilead Sciences, Inc., Tibotec Therapeutics, Roche Pharmaceuticals, Merck & Co.,
Boehringer-Ingelheim, Bristol-Myers Sqibb.
Renee Ridzon, MD
Senior Program Officer
HIV, TB, Reproductive Health
Bill & Melinda Gates Foundation
Nothing to Disclose
|
|
Disclosures: Main Article
Joseph Bick, MD
Chief Deputy, Clinical Services
California Medical Facility,
California Department of Corrections and Rehabilitation
Disclosures:
Nothing to disclose
|
|